As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...

San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to the onset of a vaso-occlusive crisis (VOC) as well as significant pain and swelling throughout the body.

Sickle cell disease summit hosted by HHS highlights advancements and challenges. Learn about the summit and the experiences ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...

Sickle cell disease is a hereditary condition, which means a person inherits it from their biological parents. The condition occurs when a person inherits two copies of the hemoglobin beta (HBB ...

The hemoglobin elevating agent is being developed for the treatment of anemia associated with multiple diseases.

Newborn screening, comprehensive care, and disease-modifying therapies are changing the outlook for patients with sickle cell ...

Topline Data from 52-week Phase 3 Study Expected in Late 2025 –CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, ...

The "Sickle Cell Disease Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering. The ...

Editas Medicine (EDIT) announced its achievement of in vivo preclinical proof of concept of hematopoietic stem and progenitor cell, HSPC, ...